MTDH is an oncogene in multiple myeloma, which is suppressed by Bortezomib treatment.
Gu C et al. Oncotarget. 2015 Dec 14. doi: 10.18632/oncotarget.6610. [Epub ahead of print].

Using “residual” FNA rinse and body fluid specimens for next-generation sequencing: An institutional experience.
Wei S et al. Cancer Cytopathol. 2015 Dec 18. doi: 10.1002/cncy.21666. [Epub ahead of print].

miR-186 inhibits cell proliferation in multiple myeloma by repressing Jagged1.
Liu Z et al. Biochem Biophys Res Commun. 2015 Dec 8. pii: S0006-291X(15)31005-6. doi: 10.1016/j.bbrc.2015.11.136. [Epub ahead of print].

Evidence for a role of the histone deacetylase SIRT6 in DNA damage response of multiple myeloma cells.
Cea M et al. Blood. 2015 Dec 16. pii: blood-2015-06-649970. [Epub ahead of print].

A novel and easy FxCycle™ violet based flow cytometric method for simultaneous assessment of DNA ploidy and six-color immunophenotyping.
Tembhare P et al. Cytometry A. 2015 Dec 15. doi: 10.1002/cyto.a.22803. [Epub ahead of print].

Genetic factors influencing the risk of multiple myeloma bone disease.
Johnson DC et al. Leukemia. 2015 Dec 16. doi: 10.1038/leu.2015.342. [Epub ahead of print].

Potential therapeutic targets in plasma cell disorders: A flow cytometry study.
Lisenko K et al. Cytometry B Clin Cytom. 2015 Dec 15. doi: 10.1002/cyto.b.21351. [Epub ahead of print].

The anti-tumoral effect of lenalidomide is increased in vivo by hypoxia-inducible factor (HIF)-1a inhibition in myeloma cells.
Storti P et al. Haematologica. 2015 Dec 11. pii: haematol.2015.133736. [Epub ahead of print].

Multi-Scale Agent-Based Multiple Myeloma Cancer Modeling and the Related Study of the Balance between Osteoclasts and Osteoblasts.
Qiao M et al. PLoS One. 2015 Dec 11;10(12):e0143206. doi: 10.1371/journal.pone.0143206. eCollection 2015.

In vivo adhesion of malignant B cells to bone marrow microvasculature is regulated by α4β1 cytoplasmic-binding proteins.
Martínez-Moreno M et al. Leukemia. 2015 Dec 10. doi: 10.1038/leu.2015.332. [Epub ahead of print].

Immunomodulatory drugs act as inhibitors of DNA methyltransferases and induce PU.1 up-regulation inmyeloma cells.
Endo S et al. Biochem Biophys Res Commun. 2015 Nov 30. pii: S0006-291X(15)30985-2. doi: 10.1016/j.bbrc.2015.11.116. [Epub ahead of print].

Targeting SDF-1 in multiple myeloma tumor microenvironment.
Bouyssou JM et al. Cancer Lett. 2015 Nov 30. pii: S0304-3835(15)00709-0. doi: 10.1016/j.canlet.2015.11.028. [Epub ahead of print].

The Role of Chemokines in Shaping the Balance Between CD4(+) T Cell Subsets and Its Therapeutic Implications in Autoimmune and Cancer Diseases.
Karin N et al. Front Immunol. 2015 Nov 30;6:609. doi: 10.3389/fimmu.2015.00609. eCollection 2015.

Corrigendum: Genome-wide association study identifies variants at 16p13 associated with survival in multiple myeloma patients.
Ziv E et al. Nat Commun. 2015 Dec 9;6:10203. doi: 10.1038/ncomms10203.

Perfusion pressure is a critical determinant of the intratumoral extravasation of oncolytic viruses.
Miller A et al. Mol Ther. 2015 Dec 9. doi: 10.1038/mt.2015.219. [Epub ahead of print].

A mathematical model of cell equilibrium and joint cell formation in multiple myeloma.
Koenders MA et al. J Theor Biol. 2015 Dec 2;390:73-79. doi: 10.1016/j.jtbi.2015.11.013. [Epub ahead of print].

Synergistic Myeloma Cell Death via Novel Intracellular Activation of Caspase 10-dependent Apoptosis by Carfilzomib and Selinexor.
Rosebeck S et al. Mol Cancer Ther. 2015 Dec 4. pii: molcanther.0488.2015. [Epub ahead of print].

Osteoclasts control reactivation of dormant myeloma cells by remodelling the endosteal niche.
Lawson MA et al. Nat Commun. 2015 Dec 3;6:8983. doi: 10.1038/ncomms9983.

Combination of a Selective HSP90α/β Inhibitor and a RAS-RAF-MEK-ERK Signaling Pathway Inhibitor Triggers Synergistic Cytotoxicity in Multiple Myeloma Cells.
Suzuki R et al. PLoS One. 2015 Dec 2;10(12):e0143847. doi: 10.1371/journal.pone.0143847. eCollection 2015.

Delivery of miR-34a by chitosan/PLGA nanoplexes for the anticancer treatment of multiple myeloma.
Cosco D et al. Sci Rep. 2015 Dec 1;5:17579. doi: 10.1038/srep17579.

Deletion of Rb1 induces both hyperproliferation and cell death in murine germinal center B cells.
He Z et al. Exp Hematol. 2015 Dec 1. pii: S0301-472X(15)00743-2. doi: 10.1016/j.exphem.2015.11.006 [Epub ahead of print].

Mechanisms for autophagy modulation by isoprenoid biosynthetic pathway inhibitors in multiple myeloma cells.
Dykstra KM et al. Oncotarget. 2015 Dec 8;6(39):41535-49. doi: 10.18632/oncotarget.6365.

Discovery of a First-in-Class, Potent, Selective, and Orally Bioavailable Inhibitor of the p97 AAA ATPase (CB-5083).
Zhou HJ et al. J Med Chem. 2015 Dec 4. [Epub ahead of print].

Junctional adhesion molecule-A is overexpressed in advanced multiple myeloma and determines response to oncolytic reovirus.
Kelly KR et al. Oncotarget. 2015 Dec 1;6(38):41275-89. doi: 10.18632/oncotarget.5753.

Cancer stem cells are the cause of drug resistance in multiple myeloma: fact or fiction?
Franqui-Machin R et al. Oncotarget. 2015 Dec 1;6(38):40496-506. doi: 10.18632/oncotarget.5800.

Study on the Association Between miRNA-202 Expression and Drug Sensitivity in Multiple Myeloma Cells.
Shen X et al. Pathol Oncol Res. 2015 Dec 21. [Epub ahead of print].

Regulatory network analysis of transcription factors, microRNAs, target genes and host genes in human multiple myeloma.
Huang Z et al. Pak J Pharm Sci. 2015 Nov;28(6 Suppl):2249-57.